Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma

Abstract

These results suggest that pamidronate may have a synergistic action with chemotherapy in decreasing osteoclastic activity, in reducing markers of myeloma activity and myeloma related pain and in improving the quality of life in patients with MM.

References

Page 1

	Year	Citations
A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine Dennis A. Hanson, Mary Ann Weis, Anne‐Marie Bollen, Journal of Bone and Mineral Research	1992	669
Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. James R. Berenson, Alan Lichtenstein, Lisa A. Porter, Journal of Clinical Oncology	1998	652
Interleukin-6 in human multiple myeloma Bernard Klein, XG Zhang, Lu Zy, Blood Hematological MalignancyAutoimmune DiseaseHematologyImmunologyPathology	1995	533
Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma R Lahtinen, Markku Laakso, I. P. Palva, The Lancet Hematological MalignancyOncologyClinical TrialsMultiple MyelomaPharmacotherapy	1992	389
A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma McCloskey, MacLennan, Mark T. Drayson, British Journal of Haematology	1998	318
In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates Ana M. Aparicio, Agnes Gardner, Yingxin Tu, Leukemia Hematological MalignancyMedicineMalignant Blood DisorderMultiple Myeloma CellsCell Transplantation	1998	267
The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. C M Shipman, Peter I. Croucher, R.G.G. Russell, PubMed Chemoprevention StrategyApoptosisImmunologyCell DeathPharmacotherapy	1998	220
Zoledronate Is a Potent Inhibitor of Myeloma Cell Growth and Secretion of IL-6 and MMP-1 by the Tumoral Environment Sophie Derenne, Martine Amiot, Sophie Barillé‐Nion, Journal of Bone and Mineral Research SclerostinPotent InhibitorBmsc ApoptosisCell DeathOsteoporosis	1999	197
Effect of daily etidronate on the osteolysis of multiple myeloma. Andrew R. Belch, Daniel E. Bergsagel, Kenneth S. Wilson, Journal of Clinical Oncology Bone DiseaseOncologyBone HealthEhdp TherapyProgressive Bone Disease	1991	180
Evidence for an autocrine/paracrine role for interleukin-6 in bone resorption by giant cells from giant cell tumors of bone. Yasuyoshi Ohsaki, Shunji Takahashi, T Scarcez, Endocrinology InflammationSclerostinBone ResorptionBone Morphogenic ProteinImmunology	1992	157

Page 1